Median Technologies launches a capital increase of 10 million euros – 07/12/2023 at 18:03

(AOF) – Median Technologies announces today the launch of a capital increase for an indicative amount of approximately 10 million euros. The company, which provides software solutions and health imaging services, specifies that this operation will consist of a private placement for institutional investors and a public offering for retail investors via the PrimaryBid platform. In the event of excess demand from investors within the framework of the Private Placement, the Company reserves the right to increase the amount raised.

In the second quarter of 2023, the company’s revenue stood at 5.8 million euros in unaudited figures, up 3.6% compared to revenue in the first quarter of 2023 and 13 .7% compared to fourth quarter 2022 revenue.

Revenue for the first half of 2023 was €11.4 million, up on revenue for the second half of 2022 (€11.1 million). Revenue is 100% derived from the iCRO ​​business, which provides services to the global biopharmaceutical industry for image management in oncology clinical trials.

The order book is 64.6 million euros at June 30, 2023, up 4.2% compared to the order book at March 31, 2023 and 6.3% compared to the order book at December 31 2022. As of June 30, 2023, the order book reached its all-time high and has been growing for 3 quarters.


Find out more about the “pharmacy” sector

Loss of speed in European research

European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.

Source link -86